Narrator: This is Science Today. A national phase II trial has found that adding the molecularly targeted drug, bortezomib, to a standard chemotherapy regimen can prolong survival in patients with advanced lung cancer by 22 percent. Study leader, Dr. Angela Davies, an assistant professor of medicine at the University of California, Davis Medical Center , says the median survival for patients with advanced lung cancer is about eight to ten months.
Davies: We were all very pleased to see a median survival of eleven months because despite the fact that we've studied many, many drugs in lung cancer, very few of them ultimately have demonstrated survival benefit in patients with lung cancer.
Narrator: Davies says they look forward to further studies in a larger, phase III trial.
Davies: I think this is the first sign that this drug in combination with chemotherapy may make a difference, but we do need to go forward to do that randomized trial and compare it against the standard treatment.
Narrator: For Science Today, I'm Larissa Branin.